In reply: Readers will probably deduce that Paul J Sambrook is no relation of Philip N Sambrook.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Sambrook PN, Chen JS, Simpson JM, March LM. Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust 2010; 193: 154-156. <MJA full text>
- 2. Lo JC, O’Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68: 243-253.
- 3. Mavrokkoki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-423.
- 4. Sambrook PN, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Phys 2006; 35: 801-803.
- 5. Boles v Merck & Co. Case no. 06-CV-9455. In re Fosamax products liability litigation, MDL 1789, US District Court, Southern District of New York (Manhattan).
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Philip Sambrook serves on the medical advisory boards of and has received speaker fees from Amgen, Merck Sharp & Dohme, Novartis, Sanofi-Aventis and Servier.